No Data
Hong Kong stocks have surged junshi bio (01877) by over 3% in the morning, obtaining the licensing rights for two dual-target fusion proteins used in the treatment of malignant tumors.
junshi bio (01877) rose more than 3% in early trading, up 2.39% as of press time, at 6.47 Hong Kong dollars, with a turnover of 6.6765 million Hong Kong dollars.
Announcement Highlights: Xiaopeng Motors reduced losses by over 50% year-on-year in the third quarter; alibaba plans to issue $2.65 billion and 17 billion RMB bonds.
Sino biopharm signed a private equity and global strategy cooperation agreement with Lixin Pharmaceuticals; zto express's revenue in the third quarter increased by 18% year-on-year to 10.68 billion yuan.
junshi bio (01877.HK) has been granted two dual-target fusion protein licensing rights.
junshi bio (01877.HK) announced the signing of a licensing agreement. The company has been granted exclusive licensing rights and sublicensing rights for the commercialization of two dual-target fusion proteins in greater china. At the same time, the company and the licensee will share the rights for the commercialization of one of the licensed products globally on a 50%:50% basis. Accordingly, the company will pay the licensee an upfront payment of 1.5 million USD; and pay milestone payments not exceeding 0.74 billion RMB. This trade's symbols are two dual-target fusion proteins mainly used for the treatment of malignant tumors. Due to the involvement of commercially sensitive information and business secrets, details regarding the trading counterpart are not disclosed.
junshi bio (688180.SH) signed a licensing agreement involving two dual-target fusion proteins for the treatment of malignant tumors.
Junshi Bio (688180.SH) announced that recently, the company signed a "License Agreement" with the licensor; the licensor grants...
Express News | junshi bio: signed a licensing agreement for two dual-target fusion proteins and will make an initial payment of 1.5 million US dollars.
Shanghai Junshi Biosciences' Unit Gets Marketing Approval for Cancer Drug by UK Regulator
No Data
No Data